Skip to main content

Table 1 Characteristic of included studies

From: Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis

AuthorYearLocationSample sizeTitle of researchAgeaStage of diseaseReason of second-line therapyInterventionControlOutcomeFollow-upb
Fradet Y [18] supplementa2019Multicentre542KEYNOTE-04565(26–86)AdvancedProgressionPembrolizumabICCOS;PFS;ORR;AEOpen
Rosenberg [19]2018Multicentre200Borealis-267(35–92)MetastaticProgressionDocetaxel plus ApatorsenDocetaxelOS;PFS;ORR;AEOpen
Powles T [20]2018Multicentre931IMvigor21167(31–88)Advanced or metastaticProgressionAtezolizumabICCOS;PFS;ORR;AEOpen
Petrylak DP [21]2017Multicentre530RANGE66(32–86)Advanced or metastaticProgressionDocetaxel plus ramucirumabDocetaxel placeboPFS;ORR;AEOpen
Jones RJ [22]2017UK131NA69(61–77)Advanced or metastaticProgressionPazopanibPaclitaxelOS;PFS;AE;QOLSOpen
Bellmunt J [23]2017Multicentre70SECAVIN63(35–80)AdvancedFailureCabazitaxelVinflunineORR;PFS;OSOpen
Petrylak DP [24]2016Multicentre148NA66(29–85)Advanced or metastaticProgressionDocetaxel plus ramucirumabDocetaxel plus icrucumabPFS;OS;ORR;SAEOpen
Santis MD [25]2016Multicentre69JASINT172(42–79)AdvancedUnfitVinflunine;GemcitabineVinflunine;CarboplatinPFS;OS;SAE;ORR25.9 M(24.3–26.5)
Noguchi M [26]2015Multicentre80NA65(46–84)AdvancedProgressionPPV plus BSCBSCPFS;OS;SAE36 M
Bellmunt J [27]2012Multicentre370NANAAdvancedFailureVinflunine;BSCBSCOS;PFS;ORR;SAE21.5 M(16.7–25.3)
Choueiri TK [28]2012Multicentre149NANAAdvanced or metastaticProgressionDocetaxel;vandetanibDocetaxel;placeboPFS;OS;SAE;ORROpen
Santis MD [29]2011Multicentre238EORTC Study 30,98671(34–87)AdvancedUnfitGemcitabine;carboplatinMethotrexate;carboplatin;vinblastineOS;PFS;ORR;SAEOpen
Culine Stephane [30]2011Frence44GETUG V0176(48–86)AdvancedUnfitGemcitabineGemcitabine;oxaliplatinORR;OS;SAEOpen
  1. BSC Best support care, ICC investigator’s choice chemotherapy, NA not available PPV personalized peptide vaccination
  2. aMedian (minimum-maximum)
  3. bOpen: follow-up until disease progress or patient death; M: months